Humana Slides as Investors Reassess 2026 Profit Recovery

Humana (HUM) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor caution after Humana’s late-July results, which beat on quarterly adjusted earnings but did not raise its full-year adjusted EPS outlook. The stock also appears to be facing lingering concern that lower Medicare Advantage Star Ratings, fast membership growth, and additional 2027 plan exits could make margin recovery harder than bulls had hoped. ([humana.gcs-web.com](https://humana.gcs-web.com/static-files/12c1ba3e-c307-42ff-9602-65887686405f))

Details:

Humana reported second-quarter 2026 adjusted EPS of $7.61 and affirmed full-year adjusted EPS guidance of at least $9.00 rather than increasing it after the quarter. ([humana.gcs-web.com](https://humana.gcs-web.com/static-files/12c1ba3e-c307-42ff-9602-65887686405f))

The company said its 2026 outlook still reflects a Star Ratings headwind, which has been weighing on bonus revenue tied to Medicare Advantage quality scores. ([humana.gcs-web.com](https://humana.gcs-web.com/static-files/12c1ba3e-c307-42ff-9602-65887686405f))

Humana is still expecting roughly 25% growth in individual Medicare Advantage membership in 2026, a positive for revenue but also a source of investor concern because new members can initially carry higher benefit ratios. ([humana.gcs-web.com](https://humana.gcs-web.com/static-files/12c1ba3e-c307-42ff-9602-65887686405f))

On the same results day, industry reporting highlighted that Humana plans to exit more Medicare Advantage plans in 2027, reinforcing the view that profitability remains the top strategic priority. ([healthcaredive.com](https://www.healthcaredive.com/editors/rparduhn/?utm_source=openai))

Sources:

Humana, Healthcare Dive, StreetInsider

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HUM Insider Trading Activity

$HUM insiders have traded $HUM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HUM stock by insiders over the last 6 months:

SANJAY K SHETTY (President, CenterWell) purchased 810 shares for an estimated $150,016

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive HUM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HUM Hedge Fund Activity

We have seen 471 institutional investors add shares of $HUM stock to their portfolio, and 424 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 3,831,860 shares (-65.9%) from their portfolio in Q1 2026, for an estimated $664,406,205
SESSA CAPITAL IM, L.P. added 1,408,833 shares (+60.8%) to their portfolio in Q1 2026, for an estimated $244,277,553
CAPITAL RESEARCH GLOBAL INVESTORS added 1,099,839 shares (+inf%) to their portfolio in Q1 2026, for an estimated $190,701,084
PZENA INVESTMENT MANAGEMENT LLC removed 1,067,846 shares (-19.5%) from their portfolio in Q2 2026, for an estimated $424,169,788
FRANKLIN RESOURCES INC removed 981,758 shares (-78.2%) from their portfolio in Q1 2026, for an estimated $170,227,019
GOLDMAN SACHS GROUP INC added 926,632 shares (+94.6%) to their portfolio in Q1 2026, for an estimated $160,668,722
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 904,125 shares (-20.2%) from their portfolio in Q2 2026, for an estimated $359,136,532

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HUM Congressional Stock Trading

Members of Congress have traded $HUM stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $HUM stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$HUM Analyst Ratings

Wall Street analysts have issued reports on $HUM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $HUM, check out Quiver Quantitative's $HUM forecast page.

$HUM Price Targets

Multiple analysts have issued price targets for $HUM recently. We have seen 16 analysts offer price targets for $HUM in the last 6 months, with a median target of $318.0.

Here are some recent targets:

Ben Hendrix from RBC Capital set a target price of $415.0 on 07/09/2026
Sarah James from Cantor Fitzgerald set a target price of $300.0 on 07/07/2026
Kevin Fischbeck from B of A Securities set a target price of $380.0 on 06/24/2026
Elizabeth Suzuki from Evercore ISI Group set a target price of $370.0 on 06/11/2026
Lisa Gill from JP Morgan set a target price of $316.0 on 06/08/2026
Ann Hynes from Mizuho set a target price of $390.0 on 06/08/2026
Erin Wright from Morgan Stanley set a target price of $249.0 on 06/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.